Literature DB >> 11688660

Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney.

O C Boerman, W J Oyen, F H Corstens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11688660     DOI： 10.1007/s002590100597

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN： 0340-6997


× No keyword cloud information.
  13 in total

1.  Kidney failure after treatment with 90Y-DOTATOC.

Authors:  Tilmann Schumacher; Christian Waldherr; Jan Mueller-Brand; Helmut Maecke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03       Impact factor: 9.236

Review 2.  Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours.

Authors:  Lisa Bodei; Marta Cremonesi; Chiara Grana; Paola Rocca; Mirco Bartolomei; Marco Chinol; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-19       Impact factor: 9.236

3.  Cubilin and megalin in radiation-induced renal injury with labelled somatostatin analogues: are we just dealing with the kidney?

Authors:  R Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10       Impact factor: 9.236

4.  Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours.

Authors:  J K Ramage; A H G Davies; J Ardill; N Bax; M Caplin; A Grossman; R Hawkins; A M McNicol; N Reed; R Sutton; R Thakker; S Aylwin; D Breen; K Britton; K Buchanan; P Corrie; A Gillams; V Lewington; D McCance; K Meeran; A Watkinson
Journal:  Gut       Date:  2005-06       Impact factor: 23.059

Review 5.  Three-dimensional imaging-based radiobiological dosimetry.

Authors:  George Sgouros; Eric Frey; Richard Wahl; Bin He; Andrew Prideaux; Robert Hobbs
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

Review 6.  Peptide-targeted radionuclide therapy for melanoma.

Authors:  Yubin Miao; Thomas P Quinn
Journal:  Crit Rev Oncol Hematol       Date:  2008-04-02       Impact factor: 6.312

7.  A stable neurotensin-based radiopharmaceutical for targeted imaging and therapy of neurotensin receptor-positive tumours.

Authors:  Elisa García-Garayoa; Peter Bläuenstein; Alain Blanc; Veronique Maes; Dirk Tourwé; P August Schubiger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-09       Impact factor: 9.236

8.  Evaluation of [64Cu]Cu-DOTA and [64Cu]Cu-CB-TE2A chelates for targeted positron emission tomography with an alphavbeta6-specific peptide.

Authors:  Sven H Hausner; David L Kukis; M Karen J Gagnon; Catherine E Stanecki; Riccardo Ferdani; John F Marshall; Carolyn J Anderson; Julie L Sutcliffe
Journal:  Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 4.488

9.  Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours.

Authors:  Andreas Helisch; Gregor J Förster; Helmut Reber; Hans-Georg Buchholz; Rudolf Arnold; Burkhard Göke; Matthias M Weber; Bertram Wiedenmann; Stanislas Pauwels; Ulrike Haus; Hakim Bouterfa; Peter Bartenstein
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-03       Impact factor: 9.236

Review 10.  Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.

Authors:  Marion de Jong; Dik Kwekkeboom; Roelf Valkema; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-02-05       Impact factor: 9.236
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.